Ohio State is enrolling patients in the national multi-center Long-term Oxygen Treatment Trial (LOTT)
Chronic obstructive pulmonary disease (COPD) is a respiratory disorder associated with chest tightness, cough, and shortness of breath with or without exertion depending on the stage of the disease. Currently, there are many available treatment options for COPD patients aiming to alleviate symptoms, reduce hospitalizations / emergency room and doctor's visits, and over all improving quality of life. Treatments include medications, smoking cessation, oxygen therapy, pulmonary rehabilitation, and surgery in some cases.
Oxygen therapy has been proven beneficial in COPD patients with severe hypoxemia (very low blood oxygen levels) at rest. However, the effectiveness of 24-hour oxygen therapy for people with COPD and moderate hypoxemia is unknown.
The Long-term Oxygen Treatment Trial (LOTT) is a multi-center, randomized clinical trial of continuous supplemental oxygen therapy versus no supplemental oxygen therapy for patients with COPD, moderate resting hypoxemia (89% - 93% on room air at rest), and increased risk of mortality. Eligible participants will be randomized to one of the two treatment groups in a 1:1 ratio. Patient randomization is expected to occur over a 3.5 year period; patient follow-up is expected to occur over a 4.5 year period. Each randomized patient is expected to be followed for a minimum of 1 year.
- Diagnosis of COPD
- FEV1 < 65% of predicted
- FEV1/FVC < 70% of predicted
- Age > 40
- Minimum of 10 pack year smoking history
- Medicare part A and B
Dr. Philip Diaz is the principle investigator at OSU. Interested individuals should be referred to OSU pulmonary clinical trials office and the contact persons are: Janice Drake 366-2287 or Mahasti Rittinger 688-4587.